Welcome to our dedicated page for Aceragen news (Ticker: ACGN), a resource for investors and traders seeking the latest updates and insights on Aceragen stock.
Aceragen, Inc. (Nasdaq: ACGN) is a clinical-stage biopharmaceutical company advancing novel therapies for rare pulmonary and rheumatic diseases. This page provides investors and industry professionals with timely updates on clinical trials, regulatory developments, and corporate milestones.
Access official announcements about ACG-701, an investigational treatment for melioidosis and cystic fibrosis exacerbations, including its FDA Fast Track and Orphan Drug designations. Stay informed about ACG-801’s development for Farber disease and strategic partnerships driving research forward.
Key updates include progress reports from ongoing studies, financial collaborations, and compliance-related disclosures. All content is sourced directly from company releases to ensure accuracy and relevance for investment research.
Bookmark this page for streamlined access to Aceragen’s latest developments in rare disease therapeutics. For comprehensive information, visit the company’s official website via the link provided below.
Aceragen, Inc. (Nasdaq: ACGN) announced that its independent Data Monitoring Committee (DMC) recommended the continuation of the TERRA Phase 2 study for ACG-701, targeting melioidosis patients. This recommendation is based on a planned safety review, allowing the trial to proceed without modifications. The TERRA study, which began in May 2022, is a randomized double-blind trial aimed at evaluating ACG-701's effectiveness in severely ill patients. The company has secured a development partnership worth approximately $50 million with the Department of Defense to explore ACG-701 as a medical countermeasure. Data read-out from the study is expected in Q4 2023.
FAQ
What is the market cap of Aceragen (ACGN)?
